Hudson Bay Capital Management
OTLK icon

Hudson Bay Capital Management’s Outlook Therapeutics OTLK Stock Holding History

Hudson Bay Capital Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-391
Closed -$213K – 493
2016
Q2 		$213K Buy
+391
New +$233K 0.01% 340

Other funds holding OTLK

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Hudson Bay Capital Management's OTLK Position: Q3 2016 in Review

Hudson Bay Capital Management sold out of Outlook Therapeutics (OTLK) in Q3 2016, closing a stake of 391 shares — an estimated $213K sold.

Hudson Bay Capital Management first reported a position in OTLK in Q2 2016 and held it in 1 quarter. The position peaked at $213K in Q2 2016. 18 funds tracked by Wall St. Rank hold OTLK as of Q3 2016.

  • Hudson Bay Capital Management reported no remaining Outlook Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Hudson Bay Capital Management sold 391 Outlook Therapeutics shares in Q3 2016, an estimated $213K.
  • Hudson Bay Capital Management first reported a position in Outlook Therapeutics in Q2 2016 and held it in 1 quarter.
  • Hudson Bay Capital Management's Outlook Therapeutics position peaked at $213K in Q2 2016.
  • 18 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2016.

Based on Hudson Bay Capital Management's 13F filing for Q3 2016, filed 9 Nov 2016.